Have any questions? [email protected] +86-21-58998590
Structure search

Ethambutol (dihydrochloride)


CAS No. : 1070-11-7

(Synonyms: Emb (dihydrochloride))

1070-11-7
Price and Availability of CAS No. : 1070-11-7
Size Price Stock
100g $87 In-stock
500g $261 In-stock
1 kg Get quote
2 kg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-B0535A
M.Wt: 277.23
Formula: C10H26Cl2N2O2
Purity: >98 %
Solubility: H2O : ≥ 50 mg/mL;DMSO : 100 mg/mL (ultrasonic)
Introduction of 1070-11-7 :

Ethambutol dihydrochloride is an antimycobacterial compound that prevents cell wall formation by inhibiting arabinosyltransferase activity. Ethambutol dihydrochloride can be used to establish animal models of hyperuricemia and optic neuropathy. In Vivo: Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Ethambutol dihydrochloride can be used in animal modeling to build a model of hyperuricemia.
1. Induction of Hyperuricaemic Disease[4][5]
Background
Elevated uric acid levels can lead to crystal deposition and may cause gout, urolithiasis, and urate nephropathy. Ethambutol dihydrochloride can cause increased uric acid levels by reducing renal uric acid clearance, ultimately leading to hyperuricemia
Specific Modeling Methods
Rat[4]: Male • Wistar rats • SPF • 200-220 g
Administration: 250 mg/kg (Ethambutol) • intragastric administration • once daily for 23 days
Note
(1) Ethambutol dihydrochloride-induced hyperuricemia model should be combined with adenine (HY-B0152) (100 mg/kg; gavage) to achieve better model construction effect[4].
(2) Some compounds can synergistically promote uric acid production, such as: Ethanol and Vitamin B12 (HY-B0315)[5].
(3) Ethambutol dihydrochloride-induced hyperuricemia model can be controlled by xanthine oxidase inhibitors.
Modeling Indicators
Molecular changes: URAT1 level in kidney homogenate ↑, OAT1 level ↓.
Physiological changes: Serum uric acid level ↑; sparse cells, tissue cell number ↑, lymphocyte number ↓.
Pathological changes: Pathological damage and inflammatory response in the thymus and spleen; thymus atrophy, cortical medullary fusion; splenic sinus congestion, with iron-yellow deposits.
Opposite Product(s): Xanthine Oxidase Inhibitors
2. Induction of Optic Neuropathy[6]
Background
Ethambutol dihydrochloride treatment can cause binocular toxicity at certain doses and durations. There is currently no clear treatment to prevent damage to retinal neuronal cells in cases of Ethhambutol dihydrochloride-induced optic neuropathy (EON).
Specific Modeling Methods
Rat: Wistar rats
Administration: 35 mg/kg/day (Ethambutol) • po • 30 days
Modeling Indicators
Molecular changes: Bcl-2, Caspase-3 expression levels ↑.
Pathological indicators: Ganglion cell damage, increased density of retinal ganglion cells (RGCs); thickening of the RGC cell layer due to vacuoles formed in the ganglion cell cytoplasm.
Opposite Product(s): Citicoline (HY-B0739)

Your information is safe with us.